Wille Finance

SwissComply AG is a company based in Zürich, Switzerland, that specializes in providing digital wealth management solutions tailored for independent wealth and asset managers, family offices, and banks. Established in 2014, SwissComply offers a modular assistance system designed to address the challenges faced by asset managers today and in the future. Its services encompass compliance and risk management, information technology, and operational support, allowing clients to optimize their processes, enhance competitiveness, reduce costs, and explore new development opportunities. The company aims to deliver a holistic and cost-effective solution that combines specialized know-how and advanced information technology to meet the evolving needs of its clientele.

Storebox is the first fully digitized self-storage solution in Europe, with more than 290 locations in Austria, Germany, Switzerland, Luxembourg, Belgium and Netherlands. The company offers storage spaces for private and business purposes, which are automatically accessible at any time. With the successful and awarded franchise system, Storebox manages to grow and will continue to expand within Europe. As a logistics partner Storebox helps to optimize last-mile logistics processes. Therefore it offers a wide range of customizable logistics solutions for business customers. There are two trends that are significant for Storebox, on the one hand urbanization and on the other hand the boom in e-commerce. Due to the growing e-commerce there are more and more empty retail spaces. Storebox has set itself the task of taking over these and transforming them into fully automated self-storage facilities. Due to increasing urbanization and the resulting downsizing of living space, it also requires more storage options. Urban development is also looking to micro hubs to enable rapid deliveries. These developments will continue and the network of storage and logistics solutions will have to become even denser. Our vision at Storeboxis clear: we shape logistics of tomorrow. To this end, we are eagerly pursuing our mission to grow into the largest and most innovative urban logistics network in Europe.

Kemiex AG operates an online B2B trading platform that facilitates the buying and selling of Active Pharmaceutical Ingredients (APIs), additives, and excipients. Founded in 2017 and based in Zurich, Switzerland, the company serves various sectors including pharmaceuticals, veterinary medicine, food, and feed industries. Kemiex provides a comprehensive marketplace that not only offers information but also streamlines the purchasing and sales processes for raw materials used in human and animal nutrition and health. By connecting buyers, sellers, and traders globally, Kemiex enhances the trading experience, allowing clients to minimize transaction lead times and maintain control over their trading activities.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Storebox is the first fully digitized self-storage solution in Europe, with more than 290 locations in Austria, Germany, Switzerland, Luxembourg, Belgium and Netherlands. The company offers storage spaces for private and business purposes, which are automatically accessible at any time. With the successful and awarded franchise system, Storebox manages to grow and will continue to expand within Europe. As a logistics partner Storebox helps to optimize last-mile logistics processes. Therefore it offers a wide range of customizable logistics solutions for business customers. There are two trends that are significant for Storebox, on the one hand urbanization and on the other hand the boom in e-commerce. Due to the growing e-commerce there are more and more empty retail spaces. Storebox has set itself the task of taking over these and transforming them into fully automated self-storage facilities. Due to increasing urbanization and the resulting downsizing of living space, it also requires more storage options. Urban development is also looking to micro hubs to enable rapid deliveries. These developments will continue and the network of storage and logistics solutions will have to become even denser. Our vision at Storeboxis clear: we shape logistics of tomorrow. To this end, we are eagerly pursuing our mission to grow into the largest and most innovative urban logistics network in Europe.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer. Recognizing the ongoing need for novel treatments despite advancements in classical therapies, T3 Pharmaceuticals aims to enhance the lives of cancer patients by developing highly specific and efficient immuno-oncology therapies. Their proprietary approach utilizes a bacterial type III secretion system to deliver therapeutic proteins directly to solid tumors, providing a potential breakthrough in cancer treatment.